BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

728 related articles for article (PubMed ID: 2156986)

  • 1. Mu antagonist and kappa agonist properties of beta-funaltrexamine (beta-FNA) in vivo: long-lasting spinal analgesia in mice.
    Qi JA; Heyman JS; Sheldon RJ; Koslo RJ; Porreca F
    J Pharmacol Exp Ther; 1990 Mar; 252(3):1006-11. PubMed ID: 2156986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methocinnamox is a potent, long-lasting, and selective antagonist of morphine-mediated antinociception in the mouse: comparison with clocinnamox, beta-funaltrexamine, and beta-chlornaltrexamine.
    Broadbear JH; Sumpter TL; Burke TF; Husbands SM; Lewis JW; Woods JH; Traynor JR
    J Pharmacol Exp Ther; 2000 Sep; 294(3):933-40. PubMed ID: 10945843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiplicative interaction between intrathecally and intracerebroventricularly administered mu opioid agonists but limited interactions between delta and kappa agonists for antinociception in mice.
    Roerig SC; Fujimoto JM
    J Pharmacol Exp Ther; 1989 Jun; 249(3):762-8. PubMed ID: 2567350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pretreatment with pertussis toxin differentially modulates morphine- and beta-endorphin-induced antinociception in the mouse.
    Tseng LF; Collins KA
    J Pharmacol Exp Ther; 1996 Oct; 279(1):39-46. PubMed ID: 8858973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Roles of mu, delta and kappa opioid receptors in spinal and supraspinal mediation of gastrointestinal transit effects and hot-plate analgesia in the mouse.
    Porreca F; Mosberg HI; Hurst R; Hruby VJ; Burks TF
    J Pharmacol Exp Ther; 1984 Aug; 230(2):341-8. PubMed ID: 6086883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kappa-opioid receptor-mediated antinociception in the rat. II. Supraspinal in addition to spinal sites of action.
    Millan MJ; Członkowski A; Lipkowski A; Herz A
    J Pharmacol Exp Ther; 1989 Oct; 251(1):342-50. PubMed ID: 2571723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of beta-funaltrexamine to determine mu opioid receptor involvement in the analgesic activity of various opioid ligands.
    Zimmerman DM; Leander JD; Reel JK; Hynes MD
    J Pharmacol Exp Ther; 1987 May; 241(2):374-8. PubMed ID: 3033213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Buprenorphine blocks epsilon- and micro-opioid receptor-mediated antinociception in the mouse.
    Mizoguchi H; Spaulding A; Leitermann R; Wu HE; Nagase H; Tseng LF
    J Pharmacol Exp Ther; 2003 Jul; 306(1):394-400. PubMed ID: 12721333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional effects of systemically administered agonists and antagonists of mu, delta, and kappa opioid receptor subtypes on body temperature in mice.
    Baker AK; Meert TF
    J Pharmacol Exp Ther; 2002 Sep; 302(3):1253-64. PubMed ID: 12183687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kappa opioids in rhesus monkeys. II. Analysis of the antagonistic actions of quadazocine and beta-funaltrexamine.
    Dykstra LA; Gmerek DE; Winger G; Woods JH
    J Pharmacol Exp Ther; 1987 Aug; 242(2):421-7. PubMed ID: 3302207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics of dose-dependent antagonism by beta-funaltrexamine of the antinociceptive effects of intrathecal mu agonists.
    Mjanger E; Yaksh TL
    J Pharmacol Exp Ther; 1991 Aug; 258(2):544-50. PubMed ID: 1650833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antidiarrheal properties of supraspinal mu and delta and peripheral mu, delta and kappa opioid receptors: inhibition of diarrhea without constipation.
    Shook JE; Lemcke PK; Gehrig CA; Hruby VJ; Burks TF
    J Pharmacol Exp Ther; 1989 Apr; 249(1):83-90. PubMed ID: 2540324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological characterization of nalorphine, a kappa 3 analgesic.
    Paul D; Pick CG; Tive LA; Pasternak GW
    J Pharmacol Exp Ther; 1991 Apr; 257(1):1-7. PubMed ID: 1850462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Agonist and antagonist activity of kappa opioids in the squirrel monkey: I. Antinociception and urine output.
    Craft RM; Dykstra LA
    J Pharmacol Exp Ther; 1992 Jan; 260(1):327-33. PubMed ID: 1309876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intrathecal beta-funaltrexamine antagonizes intracerebroventricular beta-endorphin- but not morphine-induced analgesia in mice.
    Suh HH; Tseng LF
    J Pharmacol Exp Ther; 1988 May; 245(2):587-93. PubMed ID: 2966856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence for the interaction of morphine with kappa and delta opioid receptors to induce analgesia in beta-funaltrexamine-treated mice.
    Takemori AE; Portoghese PS
    J Pharmacol Exp Ther; 1987 Oct; 243(1):91-4. PubMed ID: 2822908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.
    Wells JL; Bartlett JL; Ananthan S; Bilsky EJ
    J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Naloxone benzoylhydrazone (NalBzoH) analgesia.
    Paul D; Levison JA; Howard DH; Pick CG; Hahn EF; Pasternak GW
    J Pharmacol Exp Ther; 1990 Nov; 255(2):769-74. PubMed ID: 2173757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nalbuphine, a mixed kappa 1 and kappa 3 analgesic in mice.
    Pick CG; Paul D; Pasternak GW
    J Pharmacol Exp Ther; 1992 Sep; 262(3):1044-50. PubMed ID: 1326621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological actions of a novel mixed opiate agonist/antagonist: naloxone benzoylhydrazone.
    Gistrak MA; Paul D; Hahn EF; Pasternak GW
    J Pharmacol Exp Ther; 1989 Nov; 251(2):469-76. PubMed ID: 2553921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.